Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remibrutinib in chronic spontaneous urticaria: ambulatory blood pressure monitoring
2022-002838-13Phase 3Active
- Sponsor
- Novartis
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of remibrutinib in chronic idiopathic urticaria (CIU), sponsored by Novartis. Primary endpoint: Change in 24-hour average systolic blood pressure at Week 4 (primary safety objective). Started Nov 2022; status: active.
02
Drugs
remibrutinib
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on 2022-002838-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002838-13.